reading co-agonism threads from 2024 and half of it aged badly
reading co-agonism threads from 2024 and half of it aged badly. I have gone back and forth on this for months.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Which receptor family are you attributing that effect to?
That is preclinical work and the thread is treating it as a human finding.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.